On January 31, 2018, the European Commission has released a proposal to further harmonize the clinical assessment of new drugs. This panel will discuss the impact of a stronger collaboration on HTA within the EU. It will also provide hands-on information on how innovative biotech companies can benefit from the existing collaboration between the European HTA bodies and the European Medicines Agency and how a future European Health Technology Assessment might impact drug development.

Session ID: 1031318